MIV THERAPEUTICS' PASSIVE STENT COATINGS ACCEPTED FOR PRESENTATION AT PRESTIGIOUS WORLD CONFERENCE ON CARDIOVASCULAR THERAPY

MIV Therapeutics, Inc., a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced that interim results of a long-term animal study of its proprietary ultra-thin Hydroxyapatite coating will be featured at this year's 17th annual Transcatheter Cardiovascular Therapeutics (TCT) 2005 conference in Washington, D.C.

Yahoo Finance (http://biz.yahoo.com/bw/050912/125326.html?.v=1)